CJMB

The Company Deepened its Government Relationships at Both State and Federal Levels, Particularly to Support Onshoring Initiatives, While Reinforcing the Strength and Stability of Core Emergency Preparedness Operations Built Momentum Across Several Growth Initiatives with Healthcare and Food Manufacturing Partners SPRING BRANCH, Texas, March 31, 2026 (GLOBE NEWSWIRE) -- Callan JMB INC. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), an integrative logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services, today announced its financial results for the full year ended December 31, 2025 and is providing shareholders with a business update. “Throughout 2025 and into the new year, while our emergency preparedness business has remained the core to our operations there are several critical initiatives Callan JMB is actively pursuing with significant growth potential,” commented Wayne Williams, CEO, Chairman & Founder of Callan JMB. “Our long history and established relationships across both the state and federal levels continue to be a driver for us as potential partners seek out our knowledge and expertise. While we are focused on maintaining exceptional service levels in emergency preparedness, we are also expanding our pharmaceutical logistics and specialty distribution operations, as well as advancing U.S. onshoring initiatives. Callan JMB operates at the rigorous quality standards required for pharmaceutical distribution and our recent partnership with Attune represents a meaningful acknowledgement of our leadership in this space.” “As we look ahead into the remainder of 2026, we are focused on strengthening our core infrastructure, scaling our readiness capabilities, and advancing our strategic growth initiatives in high velocity sectors such as healthcare and food logistics. We are committed to long-term shareholder value creation by building a resilient, mission-driven organization positioned at the center of critical healthcare and national preparedness supply chains,” concluded Mr. Williams. Business Highlights to Date: Signed a manufacturing oversight, federal deployment, and commercialization agreement of multi-asset therapeutic pipeline with Biostax Corp d/b/a Attune Biotech Inc. (“Attune”), a clinical-stage biopharmaceutical company with a diversifi...

Expanded the Company’s compliance-driven logistics platform into the food sampling industry Entered agreement to install oral drug delivery equipment at Texas facility Established a subsidiary in India and advanced plans for a temperature-controlled pharmaceutical storage and distribution warehouse Extended the Company’s long-term contract with the City of Chicago through June 2026, including an increase in funding Upgraded Sentry Monitoring System Technology with Sentry 4 for Mobile Temperature Monitoring SPRING BRANCH, Texas, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Callan JMB INC. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), an integrative logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services, today announced its financial results for the third quarter ended September 30, 2025, and is providing a business update. "Callan JMB continues to execute with excellence across our core business lines, while also leveraging our key competencies to expand into target growth areas," commented Wayne Williams, CEO, Chairman & Founder of Callan JMB. "We recently launched into the food sampling sector, as a natural extension of our core capabilities and part of our multi-variant strategic growth initiatives. We have also made progress to support the onshoring of logistics operations to the U.S. in the future, particularly for international companies operating in the pharmaceutical space. This month, we entered a preliminary agreement with a maker of an innovative drug delivery system to install its manufacturing equipment in our cGMP facility in Texas, while we negotiate further operational agreements. In July, we formed Callan JMB Services (India) Private Limited, with a planned temperature-controlled warehouse for storage and distribution of pharmaceuticals at all temperature ranges." "Our emergency preparedness business continues to perform well, with the City of Chicago extending our contract through June 2026 with an additional $1.5 million in funding, bringing the total contract value to $9.1 million and reinforcing our eight-year partnership. Finally, we enhanced our technology platform by upgrading our proprietary Sentry Monitoring System to version 4.0, transitioning from Java to HTML5 to provide healthcare facilities and emergency management agencies with se...

Formed a strategic partnership with Revival Health Inc. (“Revival”) to deliver fully integrated supply chain services and infrastructure to support both the importation and onshore manufacturing of health, wellness, and longevity products Launched subsidiary in India and progressed to establish temperature-controlled warehouse for storage and distribution of pharmaceuticals at all temperature ranges Extended long-term contract with City of Chicago and received increase in funding Appointed Christopher Shields, former Assistant Commissioner of the Chicago Department of Public Health, as Senior Vice President, Emergency Preparedness & Response/Government Affairs Supported Texas and New Mexico with measles outbreak response through redistribution of MMR II vaccines SPRING BRANCH, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Callan JMB INC. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), an integrative logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services, today announced its financial results for the second quarter ended June 30, 2025 and provided a business update. "Callan JMB continues to solidify its position as a leading provider of specialized logistics solutions within high-growth opportunity markets, demonstrating our operational excellence through several key recent achievements," commented Wayne Williams, CEO, Chairman & Founder of Callan JMB. "We were proud to form a strategic partnership with Revival to develop a broad supply platform for healthcare products, changing the way they are made available across the country. In July, we further expanded our market for global pharmaceutical cold chain logistics and clinical trial support by launching a subsidiary in India to establish temperature-controlled warehouses for storage and distribution. This international expansion positions us to import critical tissue samples for clinical trials and active pharmaceutical ingredients, helping address U.S. drug shortages.” “Furthermore, we recently extended our emergency preparedness contract with the City of Chicago through June 2026 with $1.5 million in additional funding, bringing total contract value to $9.1 million. During the quarter, the Company appointed Christopher Shields as Senior Vice President, Emergency Preparedness & Response/Government Affairs,...

Revenue: US$1.45m (down 19% from 1Q 2024). Net loss: US$1.24m (loss widened by US$1.16m from 1Q 2024). US$0.32 loss per share (further deteriorated from US$0.032 loss in 1Q 2024). Our free stock report includes 3 warning signs investors should be aware of before investing in Callan JMB. Read for free now. All figures shown in the chart above are for the trailing 12 month (TTM) period Callan JMB shares are up 18% from a week ago. It's necessary to consider the ever-present spectre of investment risk. We've identified 3 warning signs with Callan JMB (at least 1 which is a bit unpleasant), and understanding these should be part of your investment process. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Completed Initial Public Offering (IPO) on February 6, 2025, at $4.00 per Share for Gross Proceeds of Approximately $5.7 Million, Including Partial Exercise of Over-Allotment Option SPRING BRANCH, Texas, May 15, 2025 (GLOBE NEWSWIRE) -- Callan JMB INC. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), an integrative logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services, today announced its financial results for the first quarter ended March 31, 2025 and is providing a business update. "Callan JMB is establishing itself as the premier provider of advanced logistics and value-added fulfillment services across high-growth sectors," stated Wayne Williams, CEO & Chairman of Callan JMB. "By leveraging our core competitive strengths, we are strategically scaling our proven business model into emerging markets where our expertise creates significant value. Our innovative solutions are disrupting traditional approaches by delivering customized configurations that precisely meet our client’s needs. We are actively pursuing growth opportunities in rapidly expanding markets, including GLP-1 pharmaceutical transportation, specialized compounding pharmacy logistics, and premium food packaging services. We are already engaged in promising discussions with potential partners in these sectors and look forward to sharing developments in the near future." "Simultaneously, we are executing a national expansion of our emergency preparedness and response operations. We have identified substantial growth potential in untapped metropolitan areas and states, and our recent appointment of Christopher Shields as Senior Vice President of Emergency Preparedness & Response/Government Affairs will accelerate our geographic expansion. Callan JMB is well positioned for sustained growth and market leadership as we progress through 2025," concluded Mr. Williams. Business Highlights to Date: On February 6, 2025, completed IPO at $4.00 per share with gross proceeds of approximately $5.7 million, including partial exercise of over-allotment. Announced the appointment of former Assistant Commissioner of the Chicago Department of Public Health, Christopher Shields, as Senior Vice President, Emergency Preparedness & Response/Government Affairs. Requested by the State of Texas Department of Hea...

Successfully Closed IPO on February 6, 2025, at $4.00 per Share for Gross Proceeds of Approximately $5.7 Million, Including Partial Exercise of Over-Allotment Option SPRING BRANCH, Texas, March 28, 2025 (GLOBE NEWSWIRE) -- Callan JMB INC. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), an integrative logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services, today announced its financial results for the full year ended December 31, 2024, and provided a business update. "2024 was a pivotal year for Callan JMB as we continued to deliver exceptional service to our diverse client base while also preparing for our IPO," said Wayne Williams, CEO & Chairman of Callan JMB. "Closing our IPO in February 2025 was an exciting milestone and a testament to our team's hard work. For years, we have been a trusted partner to both public and private sector customers, consistently delivering excellence and reliability in emergency preparedness, logistics, and fulfillment." "Looking ahead, we remain focused on scaling our existing business and expanding into new high-growth market opportunities. We are leveraging our core competitive strengths, including our proven success in thermal shipping, to capitalize on opportunities in the healthcare and food and beverage industries. Our leading end-to-end monitoring technology helps to ensure the quality and safety of shipments, giving customers confidence that their packages will arrive in pristine condition, and safeguarding patient health and consumer satisfaction. This competitive edge positions us well as we expand into GLP-1 transportation, compounding pharmacies, and high-end food packaging," concluded Mr. Williams. Business Highlights to Date: Successfully closed IPO on February 6, 2025, at $4.00 per share with gross proceeds of approximately $5.7 million including partial exercise of over-allotment. Received request from the State of Texas Department of Health and Human Services to be on standby in readiness to assist with the response to the recent outbreak of measles. Extended the Company’s arrangement with the Texas Department of State Health Services (DSHS) as the state transitions from heightened readiness to a sustainment phase following the COVID-19 pandemic. Callan will provide ongoing updates on facility and person...